// App-Quantinova.ai

POS0835 (2021) : DECLINE IN FORCED VITAL CAPACITY (FVC) IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN THE SENSCIS TRIAL VERSUS HYPOTHETICAL REFERENCE SUBJECTS WITHOUT LUNG DISEASE

Researchers

Presenter

  • T. Maher

Principal Investigators

  • A. Bourdin

  • E. Volkmann

  • S. Vettori

  • J. H. W. Distler

  • M. Alves

  • C. Stock

  • O. Distler

Medical Centers

  • Faculty of Medicine, Imperial College London, National Heart and Lung Institute, London, United Kingdom,

  • Royal Brompton Hospital, National Institute for Health Research Clinical Research Facility, London, United Kingdom

  • University of Southern California Keck School of Medicine, Los Angeles, California, United States

  • University of Montpellier, CHU Montpellier, Montpellier, France

  • University of Montpellier, CHU Montpellier, Department of Respiratory Diseases, Montpellier, France

  • University of California, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology, Los Angeles, CA, United States of America

  • Ospedale Monaldi, UOC di Fisiopatologia e Riabilitazione Respiratoria, Napoli, Italy

  • Friedrich Alexander University Erlangen-Nuremberg and Universitaetsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany

  • Boehringer Ingelheim International GmbH, Inflammation Medicine, Ingelheim am Rhein, Germany

  • University Hospital Zurich, University of Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland

Locations

  • United Kingdom

  • United States

  • France

  • Italy

  • Germany

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

Disease

  • Interstitial lung disease

  • Scleroderma

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Boehringer Ingelheim

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved